Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MBQ-167 in advanced breast cancer
NCT06075810Phase 1Recruiting
- Sponsor
- MBQ Pharma
- Start
- Nov 2023
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 1, open-label, single-arm trial of EHop-167 in breast cancer, sponsored by MBQ Pharma. Primary endpoint: Maximum Tolerated Dose at 21 days. Started Nov 2023; status: recruiting.
02
Drugs
EHop-167
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT06075810.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06075810.